OR WAIT 15 SECS
The latest happenings in the industry from the past month, all in one place.
Worldwide Clinical Trials, Inc. announced that Mike Mencer has joined the company as the EVP and General Manager of Worldwide’s Early Phase Services, focusing on the Bioanalysis Lab in Austin, Texas, and the Clinical Pharmacology Unit clinic in San Antonio, Texas.
Signant Health is proud to announce the appointment of Ian Jennings as Chief Commercial Officer.
Abond CRO announced that Susan Walker is a member of its Board of Directors.
CTI Clinical Trial and Consulting Services announced the promotions of Hadley Decker and Chris Kaas to Director of Global Training & Development and Director of Information Technology, respectively.
Almac Clinical Services announced its Just in Time Manufacturing processes have received GMP compliance certification from Ireland’s Health Products Regulatory Authority.
Signant Health is proud to announce that it has officially opened a new office facility in Blue Bell, Pennsylvania.
Spaulding Clinical Research announced that it has been awarded a five-year contract with the U.S. Food and Drug Administration Division of Applied Regulatory Science to conduct multiple clinical trials in various therapeutic areas of interest.
Clinerion partners their Patient Network Explorerwith iClusion’s Trial Eye platforms to boost the identification and recruitment of more patients into clinical trials.
Clinerion has also announced that it has gained ISO 27001:2013 certification.
PPD, Inc. has been named to Training magazine’s 2020 Training Top 125 list.
Novotech has been recognized by the Workplace Gender Equality Agency as a WGEA Employer of Choice for Gender Equality.
CROMSOURCE announced a milestone in digital management of its projects in cooperation with TECHORIZON-initiating the 1,000th trial to be managed within TheClinical digital environment.
Celerion celebrates 10 years of industry leadership providing early clinical research services to the biopharmaceutical industry.
TARGET PharmaSolutions Inc. announced the launch of its seventh observational cohort study, TARGET-ASTHMA.